Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma

NCT00813592 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Original PI left and company withdrew support.

Conditions

Cancer

Interventions

DRUG: SOM230B

Sponsor

University of Utah

Collaborators

[object Object]